Jane Street’s Orchestra BioMed OBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-15,360
Closed -$73.6K – 12540
2026
Q2
$66.3K Sell
15,360
-40,320
-72% -$165K ﹤0.01% 10809
2026
Q1
$237K Sell
55,680
-118,085
-68% -$503K ﹤0.01% 9758
2025
Q4
$721K Buy
173,765
+108,241
+165% +$437K ﹤0.01% 6886
2025
Q3
$162K Buy
65,524
+47,011
+254% +$130K ﹤0.01% 9827
2025
Q2
$49.6K Buy
+18,513
New +$54K ﹤0.01% 9176
2024
Q4
– Sell
-19,070
Closed -$98K – 10212
2024
Q3
$98K Sell
19,070
-4,712
-20% -$30.8K ﹤0.01% 8996
2024
Q2
$194K Buy
+23,782
New +$138K ﹤0.01% 8408

Other funds holding OBIO

Jane Street's OBIO Position: Q3 2026 in Review

Jane Street sold out of Orchestra BioMed (OBIO) in Q3 2026, closing a stake of 15,360 shares — an estimated $73.6K sold.

Jane Street first reported a position in OBIO in Q2 2024 and held it in 7 quarters. The position peaked at $721K in Q4 2025. 93 funds tracked by Wall St. Rank hold OBIO as of Q3 2026.

  • Jane Street reported no remaining Orchestra BioMed position as of Q3 2026 after selling out during the quarter.
  • Jane Street sold 15,360 Orchestra BioMed shares in Q3 2026, an estimated $73.6K.
  • Jane Street first reported a position in Orchestra BioMed in Q2 2024 and held it in 7 quarters.
  • Jane Street's Orchestra BioMed position peaked at $721K in Q4 2025.
  • 93 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.